Vantis Vascular announced today that it successfully closed a Series B-1 preferred financing round worth $10 million.
San Jose, California-based Vantis’ latest funding brings the company to $30 million raised to date. The company develops the CrossFast microcatheter guide extension system along with the CrossShock intravascular lithotripsy (IVL) system. It designed CrossFast to help physicians perform faster, easier and safer procedures.
DuoPro interlocking technology, a novel mechanism coupling the microcatheter to the outer delivery catheter, powers CrossFast as one unit for enhanced pushability and efficient navigation.
The guide extension catheter offers additional support and facilitates device delivery in challenging anatomies and complex, high-risk cases. Vantis won FDA clearance for CrossFast in October. The company already has the system available on a limited basis in the U.S. and plans for a full launch next year.
“We are proud to have the ongoing support of a strong group of investors who share our vision of transforming how complex interventional procedures are performed,” said Jason Turner, CEO at Vantis Vascular. “This funding is a critical milestone for Vantis and will allow us to continue our ongoing product development efforts, expand our team and initiate US commercialization of the CrossFast advanced delivery system for complex high-risk PCI procedures.”
